Endothelin receptor antagonist (ERA)

Endothelin receptor antagonist :
Endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors. Blocks the actions of endothelin. Inhibition of endothelin can reduce tumor growth, progression and angiogenesis.

three types of endothelin receptor antagonists 

(A) Selective ET A receptor antagonists such as :
sitaxentan,
ambrisentan,
atrasentan,
BQ-123 ,
zibotenten,
that affect endothelin A receptors.

(B) dual opposites such as :
bosenton,
macitentan,
tezosentan,
which affect both the endothelin A and B receptors.

(C) Selective ET B receptor antagonists such as :
BQ-788,
A192621,
Those affecting the endothelin B receptors are used in research.


Bosenton: 
Bosentan is used to treat pulmonary arterial hypertension.

Machitanton :
Macitentan is used to manage pulmonary arterial hypertension to delay the progression of the disease.

Darusentan:
Darusentan is used to treat congestive heart failure and high blood pressure.

Actelion:
Actelion is used in cardiovascular disorders, hypertension, and pulmonary hypertension.

TBC-3711 :
TBC-3711 is used for the treatment of congestive heart failure, hypertension, and pulmonary hypertension.

Sitaxenton :
Sitaxanten is used for the treatment of pulmonary hypertension, connective tissue disease, hypertension, and congestive heart failure.

Enrasentan:
Enrasentan is used for the treatment of congestive heart failure, chronic obstructive pulmonary disease (COPD), and benign prostatic hyperplasia.

BQ-123 :
BQ-123 is used for the treatment of coronary artery disease, aorto-coronary bypass grafting, and ST-elevation myocardial infarction.

AMBRISENTANE :
Ambrisentan is used for the treatment of pulmonary arterial hypertension and pulmonary arterial hypertension.
Post a Comment (0)
Previous Post Next Post